Peter Greenleaf is stepping down down as president of Gaithersburg-based biotechnology giant MedImmune, according to a company spokesman, to take the helm of parent company AstraZeneca’s Latin America business.
He will be replaced by Bahija Jallal, who currently serves as MedImmune’s executive vice president of research and development. Jallal joined the company in 2006 as vice president of translational sciences.
{iframe}http://www.washingtonpost.com/blogs/capital-business/post/peter-greenleaf-out-as-medimmune-president-bahija-jallal-chosen-as-replacement/2013/01/16/bb4fecb8-6010-11e2-a389-ee565c81c565_blog.html{/iframe}